Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2019-12-13 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
广西洲际林业投资有限公司拟了解委估林木资产市场价值资产评估报告（一）
Audit Report / Information Classification · 95% confidence The document is a detailed asset valuation report for forestry assets of Guangxi Zhouji Forestry Investment Co., Ltd., prepared by an asset appraisal company in accordance with Chinese asset appraisal standards and regulations. It includes comprehensive sections such as the purpose of the appraisal, scope, valuation methods, assumptions, conclusions, legal and regulatory references, and attachments including licenses and certificates. The document is lengthy (15,000 characters) and contains substantive financial and valuation data, not merely an announcement or summary. It is not a financial report like an annual or interim report, nor is it a regulatory filing or certification. It is a formal asset appraisal report, which aligns with the category of Audit Report / Information (AR), as it is a standalone audit/valuation report detailing applied principles and results of an asset valuation. Therefore, the appropriate classification is AR with high confidence.
2019-12-13 Chinese
关于全资子公司关联交易公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding a related-party transaction involving the company's wholly owned subsidiary and an affiliated party. It includes specifics about the transaction, pricing policies, contract terms, independent director opinions, and approvals by the board and shareholders. The document is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about a significant related-party transaction. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is a formal disclosure required by stock exchange rules about related-party transactions. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories. The document length (3092 characters) and content confirm it is not a report publication announcement or a short notice but a full regulatory disclosure.
2019-12-13 Chinese
独立董事关于关联交易的事前认可
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors regarding prior approval of a related party transaction, referencing compliance with stock exchange listing rules and company governance. It is a formal attestation or certification related to a board meeting agenda item, not a full report or announcement of voting results. The document is short (316 characters) and focuses on regulatory compliance and internal approval rather than financial data or meeting results. Therefore, it fits best under Regulatory Filings (RNS) as a compliance-related document that does not fit other categories.
2019-12-13 Chinese
关于全资子公司出售资产的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. regarding the sale of assets by its wholly-owned subsidiary. It details the transaction overview, parties involved, asset description, pricing, approvals required, and the impact on the company. The document includes board meeting resolutions and independent director opinions but does not contain comprehensive financial statements or detailed financial performance data. The length is 4269 characters, which is relatively short and the document is primarily an announcement of a transaction rather than a full financial report. It is not a regulatory certification or officer attestation. The content fits best with a Capital/Financing Update as it relates to asset sale and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-12-13 Chinese
2019年第一次临时董事会会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a company's board meeting, including approval of asset sales by subsidiaries, related party transactions, and the calling of a shareholders' meeting. It contains no financial statements or detailed financial data. It is not a full annual or interim report, nor an earnings release. It is not a proxy solicitation or voting results announcement, but a board meeting resolution announcement. The document is short (875 characters) and focuses on board decisions, so it fits best under Board/Management Information (MANG).
2019-12-13 Chinese
关于召开2019年第三次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2019 third extraordinary general meeting of shareholders for 江苏四环生物股份有限公司. It details the meeting date, voting methods (onsite and online), agenda items for shareholder approval, registration methods, and includes attachments such as proxy forms and voting instructions. There is no financial data, earnings information, or report content. The document is an announcement informing shareholders about the meeting and how to participate and vote. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2019-12-13 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.